Back
Adaptimmune Therapeutics PLC (ADAP) Earnings
ADAP Stock Price Chart
ADAP Earnings
Adaptimmune Therapeutics PLC
$0.04
-3%
$0
At close: Mar 27, 16:00:00 GMT-4
$0.04
0%
$0
Post-market: Mar 27, 20:00:00 GMT-4
Latest Earnings Results: Q2 '25
Reported: 2025-08-13
Historical Earnings
Quarterly
Annual
EPS
Revenue
Earnings FAQ
How did ADAP's recent EPS compare to expectations?
How did Adaptimmune Therapeutics PLC ADAP's revenue perform in the last quarter?
What is the revenue estimate for Adaptimmune Therapeutics PLC?
What's the earning quality score for Adaptimmune Therapeutics PLC?
When does Adaptimmune Therapeutics PLC report earnings?
What are Adaptimmune Therapeutics PLC's expected earnings?
Did Adaptimmune Therapeutics PLC beat earnings expectations?
Key Stats
Prev.Close
$0.05
Open
$0.0425
Day's Range
$0.0425 - $0.0599
52 week range
$0.0001 - $0.489
Volume
1.6M
Avg.Volume
3.8M
Dividend yield
--
EPS (TTM)
-0.11
Market Cap
$12.8M
What is ADAP?
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Features
Resources
© 2026 Finture Development Limited. All rights reserved